Year: 2023
Type: article
Abstract: HER2 (Human Epidermal Growth Factor Receptor 2)-positive breast cancer is characterized by amplification of the HER2 gene and is associated with more aggressive tumor growth, increased risk of metastasis, and poorer prognosis when compared to other subtypes of breast cancer. HER2 expression is therefore a critical tumor feature that can be used to diagnose and treat breast cancer. Moving forward, advances in HER2 in vivo imaging, involving the use of techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), may allow for a greater role for HER2 status in guiding the management of breast cancer patients. This will apply both to patients who are HER2-positive and those who have limited-to-minimal immunohistochemical HER2 expression (HER2-low), with imaging ultimately helping clinicians determine the size and location of tumors. Additionally, PET and SPECT could help evaluate effectiveness of HER2-targeted therapies, such as trastuzumab or pertuzumab for HER2-positive cancers, and specially modified antibody drug conjugates (ADC), such as trastuzumab-deruxtecan, for HER2-low variants. This review will explore the current and future role of HER2 imaging in personalizing the care of patients diagnosed with breast cancer.
Source: Journal of Clinical Medicine
DOI: 10.3390/jcm12154882
Authors: Jeremy McGale, Sakshi Khurana, Alice Huang, Tina Roa, Randy Yeh, Dorsa Shirini, Parth Doshi, Abanoub Nakhla, Maria Bebawy, David Khalil, Andrew Lotfalla, Hayley Higgins, Amit Gulati, Antoine Girard, Francois-Clement Bidard, Laurence Champion, Phuong Duong, Laurent Dercle, Romain-David Seban
Institutions: Columbia University Irving Medical Center, Memorial Sloan Kettering Cancer Center, Shahid Beheshti University, Shahid Beheshti University of Medical Sciences, Campbell University, American University of the Caribbean School of Medicine, Touro College, Maimonides Medical Center, Centre Hospitalier Universitaire Amiens-Picardie, Inserm, Université de Versailles Saint-Quentin-en-Yvelines, Institut Curie, Université Paris Sciences et Lettres, Laboratoire d'imagerie translationnelle en oncologie
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,892
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W4385250384